c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases

Journal of Gastrointestinal Oncology

Volumn 6, Issue 6, 2015, Pages 618-627

  Gayyed, Mariana Fathy ^a   Abd El Maqsoud, Nehad M R ^a   El Heeny, Amr Abd El Hameed ^a   Mohammed, Mostafa Fuad ^b  

^a Minia University   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

C MET; Colorectal adenoma; Immunohistochemistry; Metastasis; Primary colorectal carcinoma

Indexed keywords

BIOLOGICAL MARKER; SCATTER FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; COLORECTAL ADENOMA; CONTROLLED STUDY; DYSPLASIA; EGYPT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SAUDI ARABIA; SEX DIFFERENCE; UNIVERSITY HOSPITAL; UPREGULATION;

EID: 84995807192     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2015.072     Document Type: Article

References (52)

1. Parkin DM, Ferlay J, Cincidence: CI5 I-IX. Int J Cancer 2010;127:2918-27.
2. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. El-Bolkainy MN, Nouh MA, Farahat IG, et al, editors. Pathology of Cancer. Fourth edition. Cairo: Cairo Press, 2013:205.
4. Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 2007;176:61-80.
5. Frati L, Codacci-Pisanelli G. Chemotherapy and immunotherapy in metastatic colorectal cancer. N Engl J Med 2009;360:2134-5; author reply 2135-6.
6. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244:254-9.
7. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010;16:37-45.
8. Sun YL, Liu WD, Ma GY, et al. Expression of HGF and Met in human tissues of colorectal cancers: Biological and clinical implications for synchronous liver metastasis. Int J Med Sci 2013;10:548-59.
9. Mhawech-Fauceglia P, Afkhami M, Pejovic T. MET/HGF signaling pathway in ovarian carcinoma: Clinical implications and future direction. Patholog Res Int 2012;2012:960327.
10. Lee HE, Kim MA, Lee HS, et al. MET in gastric carcinomas: Comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 2012;107:325-33.
11. Raghav KP, Wang W, Liu S, et al. cMET and phosphocMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 2012;18:2269-77.
12. Felix AS, Edwards RP, Stone RA, et al. Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients. Br J Cancer 2012;106:2004-9.
13. Sun R, Zhang Q, Guo L, et al. HGF stimulates proliferation through the HGF/c-Met pathway in nasopharyngeal carcinoma cells. Oncol Lett 2012;3:1124-8.
14. Chu JS, Ge FJ, Zhang B, et al. Expression and prognostic value of VEGFR-2, PDGFR-ß, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res 2013;32:16.
15. Landi L, Minuti G, D'Incecco A, et al. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Curr Opin Oncol 2013;25:130-6.
16. Xu C, Plattel W, Van den Berg A, et al. Exprethe c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. Haematologica 2012;97:572-8.
17. Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008;99:83-9.
18. Otte JM, Schmitz F, Kiehne K, et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 2000;61:237-46.
19. Takeuchi H, Bilchik A, Saha S, et al. c-MET expression level in primary colon cancer: A predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003;9:1480-8.
20. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 2006;119:477-83.
21. Galimi F, Torti D, Sassi F, et al. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: Response to MET inhibition in patient xenografts and pathologic correlations. Clin Cancer Res 2011;17:3146-56.
22. Sotoudeh K, Hashemi F, Madjd Z, et al. The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Diagn Pathol 2012;7:57.
23. You WK, McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008;41:833-9.
24. Dienstmann R, Serpico D, Rodon J, et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012;11:2062-71.
25. Zeng ZS, Weiser MR, Kuntz E, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008;265:258-69.
26. Osada S, Matsui S, Komori S, et al. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology 2010;57:76-80.
27. Fujita S, Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn J Clin Oncol 1997;27:378-83.
28. Isaksson-Mettävainio M, Van Guelpen B, Oberg A, et al. c-Met expression in primary tumors and their corresponding distant metastases. Mol Med Rep 2008;1:787-90.
29. Hamilton SR, Vogelstein B, Kudo S. World Health Organization Classification of TuGenetics of Tumours of the Digestive System. Carcinoma of the colon and rectum. Lyon: IARC Press, 2000:103-43.
30. Treanor D, Quirke P. Pathology of colorectal cancer. Clin Oncol (R Coll Radiol) 2007;19:769-76.
31. Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012;38:451-66.
32. Richards CH, Roxburgh CS, Powell AG, et al. The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer 2014;50:309-19.
33. Shoji H, Yamada Y, Taniguchi H, et al. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci 2014;105:1002-7.
34. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011;3:S21-35.
35. Baldus SE, Kort EJ, Schirmacher P, et al. Quantification of MET and hepatocyte growth factor/scatter factor expression in colorectal adenomas, carcinomas and non-neoplastic epithelia by quantitative laser scanning microscopy. Int J Oncol 2007;31:199-204.
36. Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007;248:219-28.
37. Abou-Bakr AA, Elbasmi A. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J Oncolog 2013;1:28-34.
38. Boon EM, Van der Neut R, Van de Wetering M, et al. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 2002;62:5126-8.
39. Voutsina A, Tzardi M, Kalikaki A, et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol 2013;26:302-13.
40. Trovato M, Vitarelli E, Grosso M, et al. Immunohistochemical expression of HGF, c-MET and transcription factor STAT3 in colorectal tumors. Eur J Histochem 2004;48:291-7.
41. De Oliveira AT, Matos D, Logullo AF, et al. MET is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 2009;29:4807-11.
42. Tabuchi Y, Nakamura T, Ohno M, et al. Immunohistochemical Expression of c-Met (HGR Receptor) in Colorectal Cancer Lesions. Bulletin of Health Science Kobe 1998;14:43-48.
43. Saigusa S, Toiyama Y, Tanaka K, et al. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy. Int J Oncol 2012;40:583-91.
44. Knösel T, Schlüns K, Dietel M, et al. Chromosomal alterations in lung metastases of colorectal carcinomas: Associations with tissue specific tumor dissemination. Clin Exp Metastasis 2005;22:533-8.
45. Matsui S, Osada S, Tomita H, et al. Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway. Int J Oncol 2010;37:289-97.
46. Kojima M, Nakajima K, Ishii G, et al. Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. Am J Surg Pathol 2010;34:1351-60.
47. Puppa G, Shepherd NA, Sheahan K, et al. Peritoneal elastic lamina invasion in colorectal cancer: The answer to a controversial area of pathology. Am J Surg Pathol 2011;35:465-8.
48. Toiyama Y, Yasuda H, Saigusa S, et al. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 2012;130:2912-21.
49. Migliore C, Giordano S. Molecular cancer therapy: Can our expectation be MET? Eur J Cancer 2008;44:641-51.
50. Trusolino L, Bertotti A, Comoglio PM. MET signaling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48.
51. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16.
52. Liska D, Chen CT, Bachleitner-Hofmann T, et al. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011;17:472-82.